Core Viewpoint - Morgan Stanley's report indicates that Maogeping (01318) management's share reduction plan is expected to alleviate investor concerns regarding the expiration of the lock-up period in December 2025, leading to a slight adjustment in profit forecasts for 2025 to 2027 and an increase in target price from HKD 128 to HKD 130, maintaining a "Buy" rating and positioning Maogeping as a preferred stock in the Chinese beauty sector [1] Group 1 - The company is projected to have robust growth visibility in 2026 due to its optimal positioning in the experiential consumption trend, clear store network expansion plans, and increasing brand awareness [1] - The product line is meticulously designed to cater to Chinese facial features and aesthetics, with ongoing diversification in retail experiences [1] - A recent strategic partnership with L Catterton is expected to provide opportunities for overseas expansion and potential acquisitions [1] Group 2 - Sales and profit for Maogeping are anticipated to grow by 29% and 30% respectively in 2026, with a compound annual growth rate (CAGR) of 35% and 39% for sales and profit from 2021 to 2024, significantly outpacing industry averages of 19% and 11%, and far exceeding the retail sector's growth rate of 3% [1]

摩根大通发表报告指，2026年毛戈平的增长能见度稳健，因其在体验式消费趋势中有最佳定位、门店网 络扩张路线清晰、品牌知名度不断提升、针对中国人面部特征及审美精心设计的产品线、品类扩展，以 及持续差异化的零售体验。近期与L Catterton达成的战略合作，亦为其海外扩张及潜在并购带来机遇。 该行指出，毛戈平早前发布的管理层持股减持计划，应有助缓解投资者对2025年12月禁售期届满后的忧 虑；目标价由128港元上调至130港元，评级"增持"，列为中国美妆板块首选股份。 ...